Publications by authors named "Allison Gradone"
Increased myositis and possible myocarditis in melanoma patients treated with immune checkpoint inhibitors in the COVID-19 era.
Cancer Immunol Immunother
October 2024
Article Synopsis
- A recent study investigated the rise in cases of immune checkpoint inhibitor (ICI)-mediated myocarditis and myositis among advanced melanoma patients at a single center between 2014 and 2021.
- The analysis showed that out of 366 patients treated from 2014 to 2019, there were no cases of myocarditis, whereas from 2019 to 2021, 10 out of 246 patients (4.1%) developed myocarditis, alongside 10 cases of myositis.
- The results indicate a notable increase in these serious conditions during the COVID-19 era, suggesting a need for better risk management and treatment guidelines for affected patients.
Allogeneic hematopoietic stem cell transplant (HSCT) remains the only potentially curative treatment for many hematologic malignancies (HM). We previously developed a two-step approach that separates the lymphoid and myeloid portions of the graft, allowing a consistent T cell dosing and sparing the stem cells from the effect of post-transplant cyclophosphamide (CY). The two-step approach demonstrated safety and efficacy in patients treated with myeloablative and reduced-intensity conditioning.
View Article and Find Full Text PDFBiomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor-Induced Myocarditis.
JACC CardioOncol
December 2022
Article Synopsis
- Myocarditis is a serious side effect of immune checkpoint inhibitors (ICI), and the study aimed to see if common biomarkers could help in spotting this condition.
- Researchers looked at data from 2,606 patients treated with ICI, finding that 1% were diagnosed with myocarditis, often showing elevated levels of several biomarkers like troponin T, ALT, AST, CPK, and lactate dehydrogenase.
- Among these biomarkers, an increase in CPK was notably linked to the development of myocarditis and all-cause mortality, suggesting healthcare providers should closely monitor CPK levels during ICI treatment.